Literature DB >> 10547153

Histamine protects T cells and natural killer cells against oxidative stress.

M Hansson1, S Hermodsson, M Brune, U H Mellqvist, P Naredi, A Betten, K R Gehlsen, K Hellstrand.   

Abstract

Oxidative stress inflicted by monocytes/macrophages (MO) is recognized as an important immunosuppressive mechanism in human neoplastic disease. We report that two types of lymphocytes of relevance for protection against malignant cells, T cells and natural killer (NK) cells, became anergic to the T cell and NK cell activator interleukin-2 (IL-2) after exposure to MO-derived reactive oxygen metabolites and subsequently acquired features characteristic of apoptosis. The MO-induced anergy and apoptosis in T cells and NK cells were reversed by histamine, an inhibitor of reactive oxygen metabolite synthesis in MO. We propose that strategies to circumvent oxidative inhibition of lymphocytes may be of benefit in immunotherapy of neoplastic disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10547153     DOI: 10.1089/107999099313073

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  18 in total

1.  Individual patient data meta-analysis of randomized trials evaluating IL-2 monotherapy as remission maintenance therapy in acute myeloid leukemia.

Authors:  Marc Buyse; Pierre Squifflet; Beverly J Lange; Todd A Alonzo; Richard A Larson; Jonathan E Kolitz; Stephen L George; Clara D Bloomfield; Sylvie Castaigne; Sylvie Chevret; Didier Blaise; Dominique Maraninchi; Kathryn J Lucchesi; Tomasz Burzykowski
Journal:  Blood       Date:  2011-04-25       Impact factor: 22.113

2.  The host defense peptide LL-37 selectively permeabilizes apoptotic leukocytes.

Authors:  Ase Björstad; Galia Askarieh; Kelly L Brown; Karin Christenson; Huamei Forsman; Karin Onnheim; Hsin-Ni Li; Susann Teneberg; Olaf Maier; Dick Hoekstra; Claes Dahlgren; Donald J Davidson; Johan Bylund
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  Improving outcomes in advanced malignant melanoma: update on systemic therapy.

Authors:  Sarah Danson; Paul Lorigan
Journal:  Drugs       Date:  2005       Impact factor: 9.546

Review 4.  Alleviating oxidative stress in cancer immunotherapy: a role for histamine?

Authors:  K Hellstrand; M Brune; C Dahlgren; M Hansson; S Hermodsson; P Lindnér; U H Mellqvist; P Naredi
Journal:  Med Oncol       Date:  2000-11       Impact factor: 3.064

5.  A proinflammatory peptide from Helicobacter pylori activates monocytes to induce lymphocyte dysfunction and apoptosis.

Authors:  J Bylund; T Christophe; T Cristophe; F Boulay; A Romero; K Hellstrand; C Dahlgren
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

6.  Role of prolactin receptor and CD25 in protection of circulating T lymphocytes from apoptosis in patients with breast cancer.

Authors:  T Bauernhofer; I Kuss; U Friebe-Hoffmann; A S Baum; G Dworacki; B K Vonderhaar; T L Whiteside
Journal:  Br J Cancer       Date:  2003-04-22       Impact factor: 7.640

7.  Effects of reactive nitrogen scavengers on NK-cell-mediated killing of K562 cells.

Authors:  Yili Zeng; Qinmiao Huang; Meizhu Zheng; Jianxin Guo; Jingxin Pan
Journal:  J Biomed Biotechnol       Date:  2012-02-05

8.  Monocytes and neutrophils as 'bad guys' for the outcome of interleukin-2 with and without histamine in metastatic renal cell carcinoma--results from a randomised phase II trial.

Authors:  F Donskov; M Hokland; N Marcussen; H H Torp Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2006-01-30       Impact factor: 7.640

9.  Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.

Authors:  F Donskov; M Middleton; K Fode; P Meldgaard; W Mansoor; J Lawrance; N Thatcher; H Nellemann; H von der Maase
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640

10.  Natural killer cells modulation in hematological malignancies.

Authors:  Céline Baier; Aurore Fino; Carole Sanchez; Laure Farnault; Pascal Rihet; Brigitte Kahn-Perlès; Régis T Costello
Journal:  Front Immunol       Date:  2013-12-19       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.